Jingyuan Xu

13PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)NanophotonicsMetal cluster chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 27, 2026
Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.

|Mar 20, 2026
Antitumor Cytisine-Platinum(IV) Prodrugs Potentiate Crosstalk between Endoplasmic Reticulum and Mitochondria through Calcium Overload Accompanied by Immunogenic Cell Death.

Ruo-Xi Sang, Yang-Qi Wang, Xiu-Yuan Wu

|Jul 09, 2025
Precision-Oriented Theophylline-Platinum(IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo.

Xiao-Meng Liu, Zhen-Zhen Zhu, Qing-Tian Li

|Apr 23, 2025
Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer.

Jia-Qian Wang, Xiao-Meng Liu, Zi-Shuo Zhu

|Feb 07, 2025
Novel Indoleamine-2,3-Dioxygenase-Targeted Pt(IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo.

Zhe Li, Xiao-Meng Liu, Fei Tan

|Aug 26, 2024
Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.

Zhong-Ying Ma, Xiao-Jing Ding, Zhen-Zhen Zhu

Pageof 3

Frequent Collaborators

7 joint publications

Xin Qiao

4 joint publications

Cheng-Zhi Xie

1 joint publications

Qing-Zhong Li

1 joint publications

Si-Han Zhou